Abbott (ABT) Q2 2025 Earnings Call Transcript

Image source: The Motley Fool.Need a quote from one of our analysts? Email pr@fool.comAbbott Laboratories (NYSE:ABT) presented a quarter marked by distinct segment divergence, with medical devices sustaining double-digit organic sales growth and diagnostics constrained by COVID test declines and policy headwinds in China during Q2 2025 (non-GAAP). The company delivered high single-digit organic sales growth and margin expansion (non-GAAP) in the first half of 2025. New product milestones -- including regulatory approvals and clinical trial progress in cardiovascular and biosimilars -- indicate an acceleration of the innovation pipeline, while explicit FX forecasts offer refined visibility to investors.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool